title: Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs.
abstract: Immunohistochemical study was performed to evaluate the expression of Bcl-2 family proteins (Bcl-2, Bax, and Bad) in Walker 256 carcinosarcoma cells after implantation into the thigh muscle of male Wistar rats (10(6) cells). The experiment was conducted under conditions of spontaneous tumor development and individual or combined treatment with melatonin and cyclophosphamide. The use of melatonin as monotherapy or in combination with cyclophosphamide was followed by a significant decrease in Bcl-2 expression in carcinosarcoma cells. The Bcl-2/Bax and Bcl-2/Bad ratio was significantly reduced under these conditions (particularly after combined treatment with cytostatic drugs). These changes were accompanied by a significant (by 93.61%) decrease in the volume of transplantable tumor on day 14. Daily treatment with melatonin was accompanied by significant changes in the structure of Walker 256 carcinosarcoma. It was manifested in the formation of connective tissue septa and pseudofollicles.
authors.affiliation: Novosibirsk State Medical University, Federal Agency for Health Care and Social Development, Novosibirsk, Russia. pathol@soramn.ru
authors.forename: E V
authors.initials: EV
authors.lastname: Ovsjanko
authors.forename: E L
authors.initials: EL
authors.lastname: Lushnikova
authors.forename: P M
authors.initials: PM
authors.lastname: Larionov
authors.forename: S A
authors.initials: SA
authors.lastname: Arkhipov
authors.forename: L M
authors.initials: LM
authors.lastname: Nepomnyashchikh
authors.forename: A V
authors.initials: AV
authors.lastname: Efremov
authors.forename: Ya U
authors.initials: YU
authors.lastname: Ovsjanko
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D054697:Cytostatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008550:Melatonin / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured; D051028:bcl-2-Associated X Protein / Q000378:metabolism; D051025:bcl-Associated Death Protein / Q000378:metabolism
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D054697:Cytostatic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D051025:bcl-Associated Death Protein; D003520:Cyclophosphamide; D008550:Melatonin